Mitsubishi UFJ Trust & Banking Corp Sells 92,271 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Mitsubishi UFJ Trust & Banking Corp cut its BioNTech stake by 59.8% in Q4, selling 92,271 shares and finishing the period with 61,915 shares valued at $5.894 million.
• COO Sierk Poetting sold 50,000 shares at an average price of $110.56 under a pre-arranged Rule 10b5-1 plan, and company insiders now own 19.20% of BioNTech stock.
• BioNTech shares were down 5.7% (around $97.54), the company reported a quarterly loss (EPS -$0.39) on $1.06 billion revenue, and analysts carry a consensus "Moderate Buy" rating with a $133.13 price target.

Mitsubishi UFJ Trust & Banking Corp decreased its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 59.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,915 shares of the company's stock after selling 92,271 shares during the period. Mitsubishi UFJ Trust & Banking Corp's holdings in BioNTech were worth $5,894,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. R Squared Ltd bought a new position in BioNTech in the 4th quarter worth about $323,000. Pictet Asset Management Holding SA lifted its holdings in shares of BioNTech by 41.6% during the fourth quarter. Pictet Asset Management Holding SA now owns 88,838 shares of the company's stock valued at $8,457,000 after purchasing an additional 26,119 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of BioNTech by 2.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,075 shares of the company's stock valued at $1,721,000 after purchasing an additional 441 shares in the last quarter. B. Metzler seel. Sohn & Co. AG lifted its holdings in shares of BioNTech by 19.1% during the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 4,457 shares of the company's stock valued at $424,000 after purchasing an additional 715 shares in the last quarter. Finally, Probity Advisors Inc. lifted its holdings in shares of BioNTech by 14.2% during the fourth quarter. Probity Advisors Inc. now owns 2,863 shares of the company's stock valued at $273,000 after purchasing an additional 357 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Down 5.7%

BNTX stock opened at $97.54 on Friday. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The business's 50-day moving average is $97.52 and its two-hundred day moving average is $101.13. The company has a market cap of $24.67 billion, a price-to-earnings ratio of -18.61 and a beta of 1.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The company had revenue of $1.06 billion for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. As a group, analysts forecast that BioNTech SE Sponsored ADR will post -4.55 earnings per share for the current year.

Insider Activity at BioNTech

In other news, COO Sierk Poetting sold 50,000 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the transaction, the chief operating officer owned 399,387 shares of the company's stock, valued at $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on BNTX shares. Leerink Partners downgraded BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price target on the stock. in a report on Monday, February 2nd. Berenberg Bank reaffirmed a "buy" rating on shares of BioNTech in a report on Monday, April 13th. Bank of America reaffirmed a "buy" rating and set a $128.00 price target on shares of BioNTech in a report on Tuesday, March 10th. HC Wainwright reaffirmed a "buy" rating and set a $130.00 price target on shares of BioNTech in a report on Monday, April 27th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of BioNTech in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $133.13.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.